Mufg Securities Americas Inc. Has $4.10 Million Stock Holdings in Amgen Inc. $AMGN

Mufg Securities Americas Inc. raised its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 21.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,518 shares of the medical research company’s stock after purchasing an additional 2,601 shares during the quarter. Mufg Securities Americas Inc.’s holdings in Amgen were worth $4,097,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of AMGN. Laurel Wealth Advisors LLC boosted its stake in Amgen by 27,765.8% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock valued at $1,870,880,000 after buying an additional 6,676,575 shares in the last quarter. Norges Bank acquired a new stake in shares of Amgen in the 2nd quarter valued at $1,663,726,000. Vanguard Group Inc. grew its holdings in shares of Amgen by 1.6% in the 2nd quarter. Vanguard Group Inc. now owns 53,711,570 shares of the medical research company’s stock worth $14,996,807,000 after purchasing an additional 841,117 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Amgen by 5.6% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company’s stock worth $3,600,043,000 after purchasing an additional 687,735 shares in the last quarter. Finally, Mizuho Markets Cayman LP bought a new position in Amgen during the 2nd quarter valued at about $135,597,000. 76.50% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

AMGN has been the topic of a number of recent analyst reports. Guggenheim boosted their price target on shares of Amgen from $305.00 to $347.00 and gave the company a “neutral” rating in a research report on Friday, February 6th. Daiwa Securities Group boosted their target price on Amgen from $370.00 to $410.00 and gave the stock an “outperform” rating in a report on Tuesday, February 10th. Deutsche Bank Aktiengesellschaft raised their price target on Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a report on Thursday, February 5th. Wells Fargo & Company lifted their price objective on Amgen from $325.00 to $375.00 and gave the company an “equal weight” rating in a research report on Thursday. Finally, The Goldman Sachs Group increased their target price on Amgen from $403.00 to $415.00 and gave the stock a “buy” rating in a report on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $351.76.

Amgen Stock Up 1.2%

NASDAQ AMGN opened at $379.42 on Tuesday. The stock has a market capitalization of $204.53 billion, a P/E ratio of 26.66, a price-to-earnings-growth ratio of 3.71 and a beta of 0.46. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $385.12. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The stock has a fifty day moving average of $344.29 and a 200-day moving average of $317.21.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. The business had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities research analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, February 13th. This represents a $10.08 annualized dividend and a dividend yield of 2.7%. This is a positive change from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio is presently 70.84%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.